AstraZeneca and Elixir Software agree Global Enterprise License for iTraX
Elixir Software's Cloud-hosted Platform provides a Global Top 20 Pharma Company with responsive R&D scientific workflow management solutions
Cheshire, UK (PRWEB UK) 5 March 2015
Elixir Software Ltd, the leading provider of scientific work scheduling and workflow management solutions and services, today announced a 3 year Global Enterprise Licensing deal with AstraZeneca PLC for use of its cloud-based platform, iTraX.
AstraZeneca will continue its use of iTraX in global cross-site and external partnerships in multiple applications across R&D, and pursue further opportunities in existing and new scientific areas to improve the effectiveness and transparency of scientific delivery, which includes facilitating continued scientific communication during the relocation from Alderley Park, Cheshire to the new R&D site in Cambridge, UK.
AstraZeneca spokesman, Graeme Moody (Drug Safety & Metabolism) said "Applying complex work packages across a globally located workforce, yet responding quickly and flexibly to project demands to progress our drug portfolio, presents significant operational challenges. iTraX has simplified how we work, and has increased both the transparency and efficiency of how we deliver successful science to drug projects, using intuitive software."
Dr Matt Wood, Associate Director, (Oncology DMPK) said "iTraX has become an integral part of our (DMPK) workflow. The system has saved a significant amount of FTE time and allowed us to apply the lean process thinking of visual planning to our diverse working environment."
Elixir's innovative toolkit, iTraX, creates web-based workflow management and scheduling solutions for the tracking of work carried out within a business, and with external partners and CROs. Business solutions are securely hosted using Amazon Web Services.
The iTraX toolkit readily adapts to any process, affording highly visual board management solutions which enable secure real-time communication for all project partners, and provides unprecedented transparency and decision-making support to both managers and scientists. iTraX augments the existing use of databases through its 'sensemaking' approach, and has been successfully deployed in multiple R&D workflows including Chemistry, Discovery Sciences, DMPK and Drug Safety and Metabolism.
"We are delighted to announce this deal following 2 years of joint working with AstraZeneca, which will now deliver efficiency benefits to more projects and global personnel engaged in AstraZeneca's scientific research," said Dr Paul Faulder, CEO at Elixir Software. "A recurring theme across pharmaceutical and biotech companies is to continually reduce overheads, yet successfully manage delivery through complex workflows, representing a growth opportunity within the sector for our novel technology. The commitment from AstraZeneca validates the life science application of our unique approach as we strive to deliver similar benefits to the wider market and other industry verticals."
About Elixir Software Ltd
Elixir Software Ltd provides scalable, customised visual workflow management solutions using its 'sensemaking' toolkit, iTraX, and sets an industry standard for facile communication and collaborative working from its secure, private cloud-hosting platform accessed through any modern web-browser. Founded in 2012 by pharmaceutical industry and IT professionals, Elixir's workflow solutions are available for local deployment and on the cloud. Elixir Software Ltd is based in the UK with offices at the Alderley Park BioHub, and a customer base in pharma, biotech and research institutes across North America and Europe.
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/03/prweb12558190.htm